Mansouri Esrafil, Assarehzadegan Mohammad-Ali, Nejad-Dehbashi Fereshteh, Kooti Wesam
Cellular and Molecular Research Center, Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2018 Fall;17(4):1413-1419.
The aim of this study is to evaluate the effects of pravastatin on Adriamycin (ADR)-induced nephropathy and the mechanisms involved. Forty rats were divided into the following 4 groups: control, ADR (15 mg.kg, IP), ADR plus pravastatin (20 mg.kg which was started 5 days prior to ADR injection), and ADR plus pravastatin (20 mg.kg which was started 5 days after ADR injection). On day 20 after ADR injection, the animals were sacrificed. The results showed that administration of pravastatin decreased the levels of 24-h urinary protein (24-h UP), blood urea nitrogen (BUN), and creatinine ( < 0.05) which had increased after the injection of ADR; in addition, pravastatin reversed structural changes seen in ADR group. Furthermore, pravastatin elevated mRNA and protein expression of nephrin ( < 0.05) which had been reduced in ADR group. We conclude that pravastatin protects and treats renal injury induced by ADR.
本研究旨在评估普伐他汀对阿霉素（ADR）诱导的肾病的影响及其相关机制。将40只大鼠分为以下4组：对照组、ADR组（15mg/kg，腹腔注射）、ADR加普伐他汀组（20mg/kg，在ADR注射前5天开始给药）、ADR加普伐他汀组（20mg/kg，在ADR注射后5天开始给药）。在ADR注射后第20天，处死动物。结果显示，给予普伐他汀可降低ADR注射后升高的24小时尿蛋白（24-h UP）、血尿素氮（BUN）和肌酐水平（P<0.05）；此外，普伐他汀逆转了ADR组出现的结构变化。此外,普伐他汀提高了ADR组中降低的nephrin的mRNA和蛋白表达水平（P<0.05）。我们得出结论，普伐他汀可保护和治疗ADR诱导的肾损伤。
